February 12, 2025 11:23 AM ESTUpdated 02:17 PM
R&D

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Lei Lei Wu

News Reporter

Ab­b­Vie and Xilio Ther­a­peu­tics are part­ner­ing to make “masked” T cell en­gagers, which they hope will be safer than cur­rent­ly avail­able op­tions.

Xilio

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times